SOC2105
20 Apr 2022
Trial Summary
This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).
Acronym:
SOC2105
ACTRN/NCT /ethics:
NCT04914117
Scientific title:
Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Sponsor / Cooperative group:
RemeGen Co.
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years to 75 years |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2021-11-29 |
| Anticipated End Date | 2023-05-30 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | - |
| Recruitment Status | Recruiting |